Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR

References

• A.C. Rawstron, F.L. Bennett, S.J. O’Connor, M. Kwok, J.A. Fenton, M. Plummer, R. de Tute, R.G. Owen, S.J. Richards, A.S. Jack, and P. Hillmen, Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia, N. Engl. J. Med. 359 (2008), pp. 575–583.
   PubMed Web of Science ®Google Scholar
• M. Hallek, K. Fischer, G. Fingerle-Rowson, A.M. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, M. Bergmann, J. Catalano, P.L. Zinzani, F. Caligaris-Cappio, J.F. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trneny, A. Westermann, C.M. Wendtner, B.F. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer, Addition of rituximab to fludarabine and cyclophosphamide in patients with CLL: A randomized open-label, phase III trial, Lancet 376 (2010), pp. 1164–1174.
   Google Scholar
• K. Fischer, J. Bahlo, A.M. Fink, V. Goede, C.D. Herling, P. Cramer, P. Langerbeins, J. von Tresckow, A. Engelke, C. Maurer, G. Kovacs, M. Herling, E. Tausch, K.A. Kreuzer, B. Eichhorst, S. Böttcher, J.F. Seymour, P. Ghia, P. Marlton, M. Kneba, C.M. Wendtner, H. Döhner, S. Stilgenbauer, and M. Hallek, Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial, Blood 127 (2016), pp. 208–215.
   Google Scholar
• B. Eichhorst, A.-M. Fink, J. Bahlo, R. Busch, G. Kovacs, C. Maurer, E. Lange, H. Köppler, M. Kiehl, M. Sökler, R. Schlag, U. Vehling-Kaiser, G. Köchling, C. Plöger, M. Gregor, T. Plesner, M. Trneny, K. Fischer, H. Döhner, M. Kneba, C.-M. Wendtner, W. Klapper, K.-A. Kreuzer, S. Stilgenbauer, S. Böttcher, and M. Hallek, First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial, Lancet Oncol. 17 (2016), pp. 928–942.
   Google Scholar
• J.C. Byrd, J.R. Brown, S. O’Brien, J.C. Barrientos, N.E. Kay, N.M. Reddy, S. Coutre, C.S. Tam, S.P. Mulligan, U. Jaeger, S. Devereux, P.M. Barr, R.R. Furman, T.J. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris-Cappio, T. Robak, J. Delgado, S.J. Schuster, M. Montillo, A. Schuh, S. de Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, J.J. Jones, A.D. Chu, M. Fardis, J. McGreivy, F. Clow, D.F. James, and P. Hillmen, Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, N. Engl. J. Med. 371 (2014), pp. 213–223.
   PubMed Web of Science ®Google Scholar
• Y.T. Tai, B.Y. Chang, S.Y. Kong, M. Fulciniti, G. Yang, Y. Calle, Y. Hu, J. Lin, J.J. Zhao, A. Cagnetta, M. Cea, M.A. Sellitto, M.Y. Zhong, Q. Wang, C. Acharya, D.R. Carrasco, J.J. Buggy, L. Elias, S.P. Treon, W. Matsui, P. Richardson, N.C. Munshi, and K.C. Anderson, Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma, Blood 120 (2012), pp. 1877–1887.
   Google Scholar
• Y. Yang, J. Shi, Z. Gu, M.E. Salama, S. Das, E. Wendlandt, H. Xu, J. Huang, Y. Tao, M. Hao, R. Franqui, D. Levasseur, S. Janz, G. Tricot, and F. Zhan, Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma, Cancer Res. 75 (2015), pp. 594–604.
   Google Scholar
• L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z. Pan, D.H. Thamm, R.A. Miller, and J.J. Buggy, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc. Natl. Acad. Sci. U. S. A. 107 (2010), pp. 13075–13080.
   PubMed Web of Science ®Google Scholar
• J.J. Buggy and L. Elias, Bruton tyrosine kinase (BTK) and its role in B-cell malignancy, Int. Rev. Immunol. 31 (2012), pp. 119–132.
   Google Scholar
• J.A. Burger, A. Tedeschi, P.M. Barr, T. Robak, C. Owen, P. Ghia, O. Bairey, P. Hillmen, N.L. Bartlett, J. Li, D. Simpson, S. Grosicki, S. Devereux, H. McCarthy, S. Coutre, H. Quach, G. Gaidano, Z. Maslyak, D.A. Stevens, A. Janssens, F. Offner, J. Mayer, M. O’Dwyer, A. Hellmann, A. Schuh, T. Siddiqi, A. Polliack, C.S. Tam, D. Suri, M. Cheng, F. Clow, L. Styles, D.F. James, and T.J. Kipps, Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia, N. Engl. J. Med. 373 (2015), pp. 2425–2437.
   PubMed Web of Science ®Google Scholar
• M.L. Wang, S. Rule, P. Martin, A. Goy, R. Auer, B.S. Kahl, W. Jurczak, R.H. Advani, J.E. Romaguera, M.E. Williams, J.C. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W.W. Jedrzejczak, P. Johnson, S.E. Spurgeon, L. Li, L. Zhang, K. Newberry, Z. Ou, N. Cheng, B. Fang, J. McGreivy, F. Clow, J.J. Buggy, B.Y. Chang, D.M. Beaupre, L.A. Kunkel, and K.A. Blum, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N. Engl. J. Med. 369 (2013), pp. 507–516.
   PubMed Web of Science ®Google Scholar
• S.P. Treon, C.K. Tripsas, K. Meid, D. Warren, G. Varma, R. Green, K.V. Argyropoulos, G. Yang, Y. Cao, L. Xu, C.J. Patterson, S. Rodig, J.L. Zehnder, J.C. Aster, N.L. Harris, S. Kanan, I. Ghobrial, J.J. Castillo, J.P. Laubach, Z.R. Hunter, Z. Salman, J. Li, M. Cheng, F. Clow, T. Graef, M.L. Palomba, and R.H. Advani, Ibrutinib in previously treated Waldenstrom’s macroglobulinemia, N. Engl. J. Med. 372 (2015), pp. 1430–1440.
   PubMed Web of Science ®Google Scholar
• V. Kaur and A. Swami, Ibrutinib in CLL: A focus on adverse events, resistance, and novel approaches beyond ibrutinib, Ann. Hematol. 96 (2017), pp. 1175–1184.
   Web of Science ®Google Scholar
• W.B. Young, J. Barbosa, P. Blomgren, M.C. Bremer, J.J. Crawford, D. Dambach, S. Gallion, S.G. Hymowitz, J.E. Kropf, S.H. Lee, L. Liu, J.W. Lubach, J. Macaluso, P. Maciejewski, B. Maurer, S.A. Mitchell, D.F. Ortwine, J. Di Paolo, K. Reif, H. Scheerens, A. Schmitt, C.G. Sowell, X. Wang, H. Wong, J.M. Xiong, J. Xu, Z. Zhao, and K.S. Currie, Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834, Bioorg. Med. Chem. Lett. 25 (2015), pp. 1333–1337.
   PubMed Web of Science ®Google Scholar
• J.A. Di Paolo, T. Huang, M. Balazs, J. Barbosa, K.H. Barck, B.J. Bravo, R.A. Carano, J. Darrow, D.R. Davies, L.E. DeForge, L. Diehl, R. Ferrando, S.L. Gallion, A.M. Giannetti, P. Gribling, V. Hurez, S.G. Hymowitz, R. Jones, J.E. Kropf, W.P. Lee, P.M. Maciejewski, S.A. Mitchell, H. Rong, B.L. Staker, J.A. Whitney, S. Yeh, W.B. Young, C. Yu, J. Zhang, K. Reif, and K.S. Currie, Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis, Nat. Chem. Biol. 7 (2011), pp. 41–50.
   Google Scholar
• Y. Lou, X. Han, A. Kuglstatter, R.K. Kondru, Z.K. Sweeney, M. Soth, J. McIntosh, R. Litman, J. Suh, B. Kocer, D. Davis, J. Park, S. Frauchiger, N. Dewdney, H. Zecic, J.P. Taygerly, K. Sarma, J. Hong, R.J. Hill, T. Gabriel, D.M. Goldstein, and T.D. Owens, Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis, J. Med. Chem. 58 (2015), pp. 512–516.
   Web of Science ®Google Scholar
• D. Xu, Y. Kim, J. Postelnek, M.D. Vu, D.Q. Hu, C. Liao, M. Bradshaw, J. Hsu, J. Zhang, A. Pashine, D. Srinivasan, J. Woods, A. Levin, A. O’Mahony, T.D. Owens, Y. Lou, R.J. Hill, S. Narula, J. DeMartino, and J.S. Fine, RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents, J. Pharm. Exp. 341 (2012), pp. 90–103.
   PubMed Web of Science ®Google Scholar
• C.R. Smith, D.R. Dougan, M. Komandla, T. Kanouni, B. Knight, J.D. Lawson, M. Sabat, E.R. Taylor, P. Vu, and C. Wyrick, Fragment-based discovery of a small molecule inhibitor of Bruton’s tyrosine kinase, J. Med. Chem. 58 (2015), pp. 5437–5444.
   Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   Web of Science ®Google Scholar
• M.S. John, D. Lawson, C. Smith, H. Wang, Y.K. Chen, and T. Kanouni, Cinnoline Derivatives, US 2015038510A1, (2015).
   Google Scholar
• R.D. Cramer, 3rd, D.E. Patterson, and J.D. Bunce, Recent advances in comparative molecular field analysis (CoMFA), Prog. Clin. Biol. Res 291 (1989), pp. 161–165.
   PubMedGoogle Scholar
• R.D.C. Matthew Clark and N. Van Opdenbosch, Validation of the general purpose Tripos 5.2 force field, J. Comput. Chem. 10 (1989), pp. 982–1012.
   Google Scholar
• P.K. Balasubramanian, A. Balupuri, C.G. Gadhe, and S.J. Cho, 3D QSAR modeling study on 7-aminofuro [2,3-c] pyridine derivatives as TAK1 inhibitors using CoMFA and COMSIA, Med. Chem. Res. 24 (2014), pp. 2347–2365.
   Google Scholar
• R. Aalizadeh, E. Pourbasheer, and M.R. Ganjali, Analysis of B-Raf[Formula: see text] inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies, Molec. Div. 19 (2015), pp. 915–930.
   PubMed Web of Science ®Google Scholar
• A.R. S. Wold, H. Wold, and W. J. Dunn, The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses, SIAM J. Sci Stat. Comp. 5 (1984), pp. 735–743.
   Google Scholar
• H.P. Ron Wehrens, Lutgarde and M.C. Buydens, The bootstrap: A tutorial, Chemom. Intell. Lab. Syst. 54 (2000), pp. 35–52.
   Google Scholar
• X. Li, Y. Zuo, G. Tang, Y. Wang, Y. Zhou, X. Wang, T. Guo, M. Xia, N. Ding, and Z. Pan, Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity, J. Med. Chem. 57 (2014), pp. 5112–5128.
   Google Scholar